This is a preview of subscription content, log in via an institution to check access.
Notes
Tiotropium Safety and Performance in Respimat
see Reactions 1471 p3; 801161406
Reference
Medicines and Healthcare products Regulatory Agency (UK). Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial. Internet Document : 12 Feb 2015. Available from: URL: https://www.gov.uk/drug-safety-update/tiotropium-delivered-via-respimat-compared-with-handihaler-no-significant-difference-in-mortality-in-tiospir-trial
Rights and permissions
About this article
Cite this article
TIOSPIR: no mortality difference with Handihaler/Respimat. Reactions Weekly 1540, 7 (2015). https://doi.org/10.1007/s40278-015-7855-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-015-7855-6